Default company panoramic image

Perlstein Lab

Perlstein Lab addresses the unmet medical needs of orphan disease patients with a drug candidate generator that leaves no mutation behind.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded November 2013
  • Employees 1
  • Website

Company Summary

At the glacial pace of current orphan drug approvals, it will take 450 years to find drugs for all orphan diseases. Perlstein Lab is building a scalable and personalized orphan drug candidate generator that leverages shared genetic ancestry between individual patients and simple model organisms, with an initial focus on 49 lysosomal storage diseases. We will license drug candidates to biopharma companies and patient advocacy groups at auction.


  • Default avatar
    Ethan Oren Perlstein
    Founder and CEO

    Dr. Perlstein has spent the last 12 years in academic drug discovery, published over a dozen peer-reviewed articles and secured over $1M in funding. Dr. Perlstein validated simple model organisms for pharmacology studies in graduate school at Harvard in the lab of Prof Stuart Schreiber. Dr. Perlstein was then an independent fellow at Princeton, leading a research team that discovered novel pharmacology of antidepressant drugs.